6mgp: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
 ==Structure of human 4-1BB / 4-1BBL complex==
-<StructureSection load='6mgp' size='340' side='right' caption='[[6mgp]], [[Resolution|resolution]] 2.13&Aring;' scene=''>
+<StructureSection load='6mgp' size='340' side='right'caption='[[6mgp]], [[Resolution|resolution]] 2.13&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[6mgp]] is a 6 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MGP OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MGP FirstGlance]. <br>
+<table><tr><td colspan='2'>[[6mgp]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MGP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6MGP FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.13&#8491;</td></tr>
-<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6mge|6mge]]</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
-<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6mgp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mgp OCA], [http://pdbe.org/6mgp PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6mgp RCSB], [http://www.ebi.ac.uk/pdbsum/6mgp PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6mgp ProSAT]</span></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6mgp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mgp OCA], [https://pdbe.org/6mgp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6mgp RCSB], [https://www.ebi.ac.uk/pdbsum/6mgp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6mgp ProSAT]</span></td></tr>
 </table>
 == Function ==
-[[http://www.uniprot.org/uniprot/TNFL9_HUMAN TNFL9_HUMAN]] Cytokine that binds to TNFRSF9. Induces the proliferation of activated peripheral blood T-cells. May have a role in activation-induced cell death (AICD). May play a role in cognate interactions between T-cells and B-cells/macrophages. [[http://www.uniprot.org/uniprot/TNR9_HUMAN TNR9_HUMAN]] Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.
+[https://www.uniprot.org/uniprot/TNR9_HUMAN TNR9_HUMAN] Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+-1BB (CD137, TNFRSF9) is an inducible costimulatory receptor expressed on activated T cells. Clinical trials of two agonist antibodies, utomilumab (PF-05082566) and urelumab (BMS-663513), are ongoing in multiple cancer indications, and both antibodies demonstrate distinct activities in the clinic. To understand these differences, we solved structures of the human 4-1BB/4-1BBL complex, the 4-1BBL trimer alone, and 4-1BB bound to utomilumab or urelumab. The 4-1BB/4-1BBL complex displays a unique interaction between receptor and ligand when compared with other TNF family members. Furthermore, our ligand-only structure differs from previously published data. Utomilumab, a ligand-blocking antibody, binds 4-1BB between CRDs 3 and 4. In contrast, urelumab binds 4-1BB CRD-1, away from the ligand binding site. Finally, cell-based assays demonstrate utomilumab is a milder agonist than urelumab. Collectively, our data provide a deeper understanding of the 4-1BB signaling complex, providing a template for future development of next generation 4-1BB targeted biologics.
+Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.,Chin SM, Kimberlin CR, Roe-Zurz Z, Zhang P, Xu A, Liao-Chan S, Sen D, Nager AR, Oakdale NS, Brown C, Wang F, Yang Y, Lindquist K, Yeung YA, Salek-Ardakani S, Chaparro-Riggers J Nat Commun. 2018 Nov 8;9(1):4679. doi: 10.1038/s41467-018-07136-7. PMID:30410017<ref>PMID:30410017</ref>
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+</div>
+<div class="pdbe-citations 6mgp" style="background-color:#fffaf0;"></div>
+==See Also==
+*[[Tumor necrosis factor ligand superfamily 3D structures|Tumor necrosis factor ligand superfamily 3D structures]]
+*[[Tumor necrosis factor receptor 3D structures|Tumor necrosis factor receptor 3D structures]]
+== References ==
+<references/>
 __TOC__
 </StructureSection>
-[[Category: Chin, S M]]
+[[Category: Homo sapiens]]
-[[Category: Kimberlin, C R]]
+[[Category: Large Structures]]
-[[Category: Roe-Zurz, Z]]
+[[Category: Chin SM]]
-[[Category: Xu, A]]
+[[Category: Kimberlin CR]]
-[[Category: Yang, Y]]
+[[Category: Roe-Zurz Z]]
-[[Category: 4-1bb]]
+[[Category: Xu A]]
-[[Category: 4-1bbl]]
+[[Category: Yang Y]]
-[[Category: Cd137]]
-[[Category: Cd137l]]
-[[Category: Complex]]
-[[Category: Immune system]]
-[[Category: Signaling]]
-[[Category: Tnfrsf]]
-[[Category: Tnfsf]]